NCT03470701

Brief Summary

This study will test the effectiveness of mailed, smartphone urinalysis kits to improve albuminuria screening compliance and detection of albuminuria.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
999

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 13, 2018

Completed
6 days until next milestone

Study Start

First participant enrolled

March 19, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 20, 2018

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 19, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 19, 2018

Completed
Last Updated

July 24, 2018

Status Verified

July 1, 2018

Enrollment Period

3 months

First QC Date

March 13, 2018

Last Update Submit

July 23, 2018

Conditions

Outcome Measures

Primary Outcomes (2)

  • Completion of albuminuria screening

    Includes completion of mailed smartphone urinalysis and clinical labs (urinalysis, albumin/creatinine ratio, or protein/creatinine ratio)

    Baseline to 3 months of enrollment date

  • Total number of detected albuminuria cases

    confirmed by urine albumin/creatinine ratio \>= 30 mg/g

    Baseline to 3 months of enrollment date

Study Arms (2)

Control - usual care

NO INTERVENTION

This arm will receive usual care.

Mailed Urinalysis Smartphone Kit

EXPERIMENTAL

This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.

Other: Mailed Urinalysis Smartphone Kit

Interventions

Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.

Mailed Urinalysis Smartphone Kit

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • and older
  • Hypertension
  • Last outpatient BP ≥ 130/80 mmHg
  • Active MyGeisinger users with a listed mobile phone number
  • Has a Geisinger PCP and followed by the Care Gaps team
  • No prior urine albuminuria test (urine dipstick, albumin/creatinine ratio, protein/creatinine ratio)

You may not qualify if:

  • History of diabetes
  • Receiving dialysis
  • History of kidney transplant
  • eGFR \< 15 ml/min/1.73m2
  • Principal investigator or PCP discretion (i.e. concerns about safety, compliance)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Geisinger Health System

Danville, Pennsylvania, 17821, United States

Location

Related Publications (1)

  • Leddy J, Green JA, Yule C, Molecavage J, Coresh J, Chang AR. Improving proteinuria screening with mailed smartphone urinalysis testing in previously unscreened patients with hypertension: a randomized controlled trial. BMC Nephrol. 2019 Apr 18;20(1):132. doi: 10.1186/s12882-019-1324-z.

MeSH Terms

Conditions

AlbuminuriaRenal Insufficiency, ChronicCardiovascular DiseasesHypertension

Condition Hierarchy (Ancestors)

ProteinuriaUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsRenal InsufficiencyKidney DiseasesChronic DiseaseDisease AttributesPathologic ProcessesVascular Diseases

Study Officials

  • Alex R Chang, MD

    Geisinger Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

March 13, 2018

First Posted

March 20, 2018

Study Start

March 19, 2018

Primary Completion

June 19, 2018

Study Completion

June 19, 2018

Last Updated

July 24, 2018

Record last verified: 2018-07

Locations